close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

DMA Forecasts $10.6 Billion in 2008 Pharmaceutical Sales via Direct Marketing; New Report Focuses on Pharmaceutical Industry

NEW YORK, April 10, 2008 — This year, pharmaceutical companies are forecast to generate $10.6 billion in sales through direct marketing, and that figure is expected to hit $15.2 billion in 2012.  These are key findings in a new Direct Marketing Association (DMA) report entitled “Direct Marketing Facts and Figures in the Pharmaceutical Industry.”

 

DMA’s new 127-page report provides pharmaceutical direct marketers with a comprehensive overview of their sector.  Each of its nine chapters — Pharmaceutical Overview; Catalogs; Commercial Email; Direct Mail; Insert Media; Internet Marketing; Print Media; Broadcast Media; and Telephone Marketing — is broken down into three subsets of data — direct marketing spending, sales, and employment — and then further examined by market and intent of offer.

 

The report also contains more than 70 charts that help readers benchmark their own direct marketing progress.

 

According to DMA Research Manager Michelle Tiletnick, “Initially, DMA was going to include the pharmaceutical industry as part of our healthcare report, which was published in February.  However, upon review of the information, we realized that pharmaceutical and healthcare marketers were different enough that each merited its own report.”

 

“Readers of our pharmaceutical report will certainly find that the American pharmaceutical industry employs direct marketing extensively and successfully,” Tiletnick said.  “This report will help pharmaceutical marketers benchmark their current direct marketing efforts against the entire industry as well as prepare themselves for the coming years.”

 

Other key findings from “Direct Marketing Facts and Figures in the Pharmaceutical Industry” include:

 

·         In 2008, pharmaceutical direct marketers will spend more than $1 billion on direct marketing, reap revenues of $10.6 billion, and see an advertising ROI of $10.27 on each $1 spent.

 

·         Between 2007 and 2012, direct marketing-driven sales are projected to compound 9.4 percent annually.

 

·         The business-to-business category is responsible for nearly 65 percent of pharmaceutical direct mail advertising today.

 

·         Commercial email spending is projected to increase 21.9 percent each year from 2007 to 2012.

 

·         In 2012, Internet advertising expenditures will be nearly $173 million, up from an expected $93.6 million this year. 

 

·         Direct marketing-driven Web-driven sales this year will total nearly $1.9 billion and by 2012 they will double — reaching nearly $3.8 billion.

 

·         Print marketing will generate more than $2 billion in sales this year.

 

·         Between 2007 and 2012, direct mail spending is forecast to grow 7.1 percent each year.

 

·         Insert media sales is expected to surpass $41 million in 2008.

 

The cost of “Direct Marketing Facts and Figures in the Pharmaceutical Industry” is $135 for DMA members and $240 for non-members.  The report is available now for downloading at DMA’s Bookstore.  To purchase, click here.

 

The cost of “Direct Marketing Facts and Figures in the Health Services Industry” is $135 for DMA members, and $240 for non-members.  The report available now for downloading at DMA’s Bookstore.  To purchase, click here.


1120 Avenue of the Americas          
New York, NY 10036-6700
Telephone: 212.768.7277
Fax: 212.302.6714

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...